A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Summary

This phase II trial studies the best approach to combine chemotherapy and radiation therapy (RT) based on the patient's response to induction chemotherapy in patients with non-germinomatous germ cell tumors (NGGCT) that have not spread to other parts of the brain or body (localized). This study has 2 goals: 1) optimizing radiation for patients who respond well to induction chemotherapy to diminish spinal cord relapses, 2) utilizing higher dose chemotherapy followed by conventional RT in patients who did not respond to induction chemotherapy.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Central Nervous System Nongerminomatous Germ Cell Tumor
• Choriocarcinoma
• Embryonal Carcinoma
• Immature Teratoma
• Malignant Teratoma
• Mixed Germ Cell Tumor
• Pineal Region Germ Cell Tumor
• Pineal Region Immature Teratoma
• Pineal Region Yolk Sac Tumor
• Suprasellar Germ Cell Tumor

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

3 to 29 years

Sex

All

Healthy volunteers

Not accepted

Sponsor

Children's Oncology Group

Last updated on ClinicalTrials.gov

September 23, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites